Inhibikase Therapeutics Cash Flow Statement Analysis

Operating, investing, and financing activities in millions USD

Scroll to see more
Cash flow statement showing operating, investing, and financing activities for Inhibikase Therapeutics, Inc. (IKT) - Annual data in millions USD
BreakdownFY 2024FY 2023FY 2022FY 2021FY 2020
Period EndingDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Operating Activities
Net Income-27.52-19.03-18.05-14.79-2.85
Depreciation & Amortization0.030.180.010.000.00
Stock Based Compensation8.140.500.461.530.57
Change in Working Capital0.200.230.17-1.76-0.46
Change in Accounts Receivable0.000.040.07-0.110.00
Change in Accounts Payable0.27-0.500.06-0.63-0.25
Change in Other Working Capital-0.070.030.071.30-1.11
Other Operating Activities0.000.030.070.721.61
Net Cash from Operating Activities-19.15-18.09-17.35-14.30-1.13
Investing Activities
Capital Expenditures0.00-0.01-0.240.000.00
Purchases of Investments-37.00-29.43-20.730.000.00
Sales/Maturities of Investments23.4541.104.960.000.00
Net Cash from Investing Activities-37.0011.66-16.010.000.00
Financing Activities
Debt Repayment0.000.00-0.25-0.040.00
Common Stock Issued103.488.540.0441.2114.79
Common Stock Repurchased0.000.000.00-0.080.00
Other Financing Activities0.00-0.140.00-0.080.00
Net Cash from Financing Activities103.488.41-0.2041.0915.06
Summary
Net Change in Cash47.331.98-33.5626.8013.94
Cash at Beginning of Period9.177.1940.7513.950.00
Cash at End of Period56.499.177.1940.750.00
Free Cash Flow-19.15-18.10-17.59-14.30-1.13
Supplemental Disclosures
Interest Paid0.000.000.000.000.01